标签归档：sacituzumab

Sacituzumab govitecan(Synonyms: IMMU-132)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sacituzumab govitecan (Synonyms: IMMU-132)

Sacituzumab govitecan (IMMU-132) 是一种抗体-药物偶联物 (ADC)，靶向 Trop-2 传递 SN-38。Sacituzumab govitecan 具有抗癌活性。

Sacituzumab govitecan(Synonyms: IMMU-132)

Sacituzumab govitecan Chemical Structure

CAS No. : 1491917-83-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1].

体内研究
(In Vivo)

Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) results in significant anti-tumor effects in mice bearing human gastric cancer xenografts[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
CAS 号

1491917-83-9
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Sacituzumab

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Sacituzumab 

Sacituzumab 是一种人源化 IgG1 单克隆抗体，与抗滋养层细胞表面抗原 2 (anti-Trop-2) 结合。Sacituzumab 具有用于转移性三阴性乳腺癌研究的潜力。

Sacituzumab

Sacituzumab Chemical Structure

CAS No. : 1796566-95-4

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Trastuzumab is a humanized IgG1 monoclonal antibody for anti-trophoblast cell-surface antigen 2 (anti-Trop-2). Sacituzumab has the potential for metastatic triple-negative breast cancer research[1].

CAS 号

1796566-95-4
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. A Bardia, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务